Skip to content

XOMA Corporation XOMA Operating Income

Operating Income at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$17.37M+148%
Royalty Pharma logo
Royalty PharmaRPRX
$563.04M+5.4%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$9.48M+34.3%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$38.15M-7.9%
Zymeworks logo
ZymeworksZYME
-$47.12M-84.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$169M-18.2%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$745.16M+159%
Enterprise value$784.29M+151%
P/E22×
P/S15.4×+8.6×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's operating income?
XOMA Corporation (XOMA) reported operating income of -$480K in Q1 2026.
How has XOMA Corporation's operating income changed year-over-year?
XOMA Corporation's operating income decreased by 108.1% year-over-year, from $5.93M to -$480K.
What is the long-term trend for XOMA Corporation's operating income?
Over 4 years (2021 to 2025), XOMA Corporation's operating income has grown at a -10.2% compound annual growth rate (CAGR), from $17.53M to $11.38M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.